| Meningococcal infection and its effective vaccines | 
								
								  | K Abedini *    ,  M Darvishi    ,  S Zareiy    ,  M Samadpoor    ,  A Eskandari    | 
								
								  |  | 
								
								  |  | 
                                
								  | Abstract:       (5974 Views) | 
								
								  | Neisseria meningitidis is a leading cause of bacterial meningitis and other invasive bacterial infections, both in the United States and worldwide. The role of the meningococcus as a cause of bacterial meningitis has become more important in recent years with the declines in meningitis caused by Haemophilus influenzae type b and Streptococcus pneumoniae because of the introduction of new conjugate vaccines, Listeria because of efforts to reduce the contamination of food with L. monocytogenes, and group B streptococcus because of the use of chemoprophylaxis during parturition in women.
The development of a pneumococcal vaccine six decades ago demonstrated the feasibility of vaccine prevention of invasive encapsulated bacterial diseases. Purified polysaccharide vaccines for serogroups A and C N. meningitidis were developed several decades later. Early vaccines were poorly immunogenic apparently because the polysaccharides that were used were of low molecular weight, whereas vaccines made from polysaccharide with a molecular weight over 100,000 had excellent immunogenicity.
Meningococcal conjugate vaccines, are typically T-cell dependent, which as regards of immunologic improvements over polysaccharide vaccines. The carrier proteins used for meningococcal conjugate vaccines have included tetanus toxoid protein, diphtheria toxoid, and diphtheria cross-reactive material (CRM)197.
The immunogenicity of a variety of outer membrane protein- based serogroup B vaccines has been studied. In an evaluation of three doses of a Cuban B:4:P1.15 vaccine and a Norwegian B:15:P1.7,16 showed that more than two-thirds of children and adults had at least a fourfold rise in SBA, as did at least 90% of infants | 
								
								  |  | 
								
								  | Keywords:  N. meningitides, Vaccine, Meningococcal infection | 
								
								  |  | 
								
								  | Full-Text  [PDF 268 kb] 
                                    
                                     
                                     
                                    
									  
                                       (3323 Downloads) | 
								
								  | Type of Study:  Original | Received: 2014/09/8 | Accepted: 2014/09/8 | Published: 2014/09/8
 | 
                                
                                  
                                    |  | 
								
								  |  | 
								
								  |  | 
								
								  |  | 
								
								  | Add your comments about this article | 
                                
                                |  | 
								
								  |  |